KPTIQ
KPTIQ clinical trials: Karyopharm Therapeutics Inc.
Every trial on ClinicalTrials.gov where Karyopharm Therapeutics Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 95
- Trials linked
- 37
- As lead sponsor
- 58
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
KPTIQ on the catalyst calendar · KPTIQ registry changes
- Primary completion Jun 2, 2026ActualPhase 2NCT02227251Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Karyopharm Therapeutics Inc · Diffuse Large B-cell LymphomaTerminatedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 20, 2026ActualPhase 3NCT04562389Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisKaryopharm Therapeutics Inc · MyelofibrosisActive, not recruitingKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 22, 2026ActualPhase 3NCT05611931Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaKaryopharm Therapeutics Inc · Endometrial CancerActive, not recruitingKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 2NCT04414475A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in...Karyopharm Therapeutics Inc · Multiple Myeloma, RefractoryRecruitingKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2/Phase 3NCT04442022A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse...Karyopharm Therapeutics Inc · Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2024ActualPhase 1/Phase 2NCT04256707Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor...Karyopharm Therapeutics Inc · Non-Small Cell Lung Carcinoma (NSCLC)CompletedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 1/Phase 2NCT02343042Selinexor and Backbone Treatments of Multiple Myeloma PatientsKaryopharm Therapeutics Inc · Multiple MyelomaRecruitingKPTIQLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2026Sponsor estimatePhase 2NCT04562870A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisKaryopharm Therapeutics Inc · MyelofibrosisActive, not recruitingKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 22, 2022ActualPhase 3NCT03555422Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]Karyopharm Therapeutics Inc · Endometrial CancerCompletedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT07215832Karyopharm Expanded Access Program for SelinexorKaryopharm Therapeutics Inc · Multiple MyelomaAvailableKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 2NCT05980806A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaKaryopharm Therapeutics Inc · MyelofibrosisRecruitingKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025Sponsor estimatePhase 1/Phase 2NCT04607772Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse...Karyopharm Therapeutics Inc · Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2024ActualPhase 1/Phase 2NCT02649790Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsKaryopharm Therapeutics Inc · Relapsed/Refractory Multiple Myeloma (RRMM)CompletedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 3, 2023ActualPhase 1/Phase 2NCT04421378A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent GlioblastomaKaryopharm Therapeutics Inc · Glioblastoma MultiformeTerminatedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 26, 2021ActualPhase 1NCT02702492PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)Karyopharm Therapeutics Inc · Solid TumorsTerminatedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2023ActualPhase 2NCT04768881Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaKaryopharm Therapeutics Inc · Locally Advanced Unresectable or Metastatic MelanomaTerminatedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 18, 2020ActualPhase 3NCT03110562Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaKaryopharm Therapeutics Inc · Multiple MyelomaCompletedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 24, 2022ActualPhase 2NCT04854434A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated...Karyopharm Therapeutics Inc · Metastatic Colorectal CancerTerminatedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 21, 2016ActualPhase 1NCT01896505A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With SarcomaKaryopharm Therapeutics Inc · SarcomaCompletedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2017Sponsor estimatePhase 2NCT02628704Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple MyelomaKaryopharm Therapeutics Inc · Multiple MyelomaWithdrawnKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2017Sponsor estimatePhase 2NCT02431351Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome PatientsKaryopharm Therapeutics Inc · Myelodysplastic SyndromeWithdrawnKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2018Sponsor estimatePhase 1/Phase 2NCT02389543Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsKaryopharm Therapeutics Inc · Multiple MyelomaWithdrawnKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 26, 2019ActualPhase 2NCT02336815Selinexor Treatment of Refractory MyelomaKaryopharm Therapeutics Inc · Multiple MyelomaCompletedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2016ActualPhase 2NCT02314247Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell LymphomaKaryopharm Therapeutics Inc · Peripheral T-cell Lymphoma (PTCL)TerminatedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 10, 2015ActualPhase 2NCT02213133Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell CarcinomasKaryopharm Therapeutics Inc · Squamous Cell CarcinomaTerminatedKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 70 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner